Duncan_Andison / iStockphoto.com
The Patent Trial and Appeal Board (PTAB) has rejected Celltrion’s challenge against a Genentech patent centring on a method of treating rheumatoid arthritis, stating that the challenged patent did not show any reasonable likelihood of being invalid.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
PTAB, USPTO, Celltrion, patent, IPR, Genentech
